1. Scrip
  2. >>Rare Diseases

Can UCB Make Its Mark In Myasthenia Gravis?

Playing Catch-Up With Alexion And Argenx

 
• By Kevin Grogan

The Belgian drugmaker has presented positive data on its two submission-ready generalized myasthenia gravis drugs zilucoplan and rozanolixizumab but analysts are concerned that their efficacy will not differentiate them sufficiently to challenge Vyvgart and Soliris/Ultomiris.

Market share
UCB hopes to get a decent slice of the myasthenia gravis market • Source: Shutterstock

UCB S.A. has presented more data on zilucoplan and rozanolixizumab, two late-stage therapies for generalized myasthenia gravis (gMG) but observers are sceptical about the pair's prospects of challenging the new drug on that particular rare disease block, argenx N.V.'s Vyvart.

The Belgian firm has unveiled detailed results from two Phase III trials of the two drugs for gMG, which causes...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

More from Scrip

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?